Neovacs announces an agreement with Biosyn GmbH to diversify its supply of Keyhole Limpet Hemocyanin (KLH)
April 01 2019 - 1:30AM
Neovacs announces an agreement with Biosyn GmbH to diversify its
supply of Keyhole Limpet Hemocyanin (KLH)
PRESS RELEASE ·
PRESS RELEASE · PRESS
RELEASE
NEOVACS ANNOUNCES AN AGREEMENT WITH
BIOSYN GmbH TO DIVERSIFY ITS
SUPPLY OF KEYHOLE LIMPET HEMOCYANIN (KLH)
Paris et Boston, april 1st 2019 - 07h30
CEST - Neovacs (Euronext Growth Paris: ALNEV), leader in
active immunotherapy for the treatment of auto-immune diseases,
today announces that the company has signed a new supply agreement
with the German company biosyn GmbH to diversify its sourcing of
KLH, one of the three components required to manufacture its
therapeutic vaccine IFNα Kinoid.
As a pre-requisite to this supply agreement,
Neovacs has validated the protein produced by biosyn GmbH to meet
the needs for the development of the manufacturing process of the
IFNα Kinoid vaccine and the phase III clinical batches
requirements, as well as for the future market launch.
KLH produced by biosyn GmbH is registered as a
bladder cancer drug in key pharmaceutical markets, including two
European Countries. It is also used as a carrier protein for
conjugated vaccines manufacturing. This raw material is GMP grade
and its regulatory file is regularly updated.
About biosyn
biosyn Arzneimittel GmbH is a pharmaceutical and
biotech company based in Fellbach, Germany. It specializes in trace
elements, is a world market leader for high-dose selenium
injections,developer and operator of two unique GMP manufacturing
operations for producing active ingredients, and in the biotech
sector, is actively involved in the production of glycoprotein
isolated from the Megathura crenulata, a sea snail found in
California.
About NeovacsListed on Euronext
Growth since 2010, Neovacs is today a leading biotechnology company
focused on an active immunotherapy technology platform (Kinoids)
with applications in autoimmune and/or inflammatory diseases. On
the basis of the company’s proprietary technology for inducing a
polyclonal immune response (covered by four patent families that
potentially run until 2032) Neovacs is focusing its clinical
development efforts on IFNα-Kinoid, an immunotherapy being
developed for the indication of lupus, dermatomyositis and also in
preclinical trial for Type 1 diabetes. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the
fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe
treatments with efficacy that is sustained in these life-long
diseases. www.neovacs.fr
Contacts
NéovacsCorporate
Communication& Investor
RelationsCharlène Masson+33 1 53 10 93
00cmasson@neovacs.com |
Media
Relation NewCapAnnie-Florence
LoyerTél : +33 (0)6 88 20 35 59 / +33 (0)1 44 71 00
12afloyer@newcap.frLéa JacquinTel : +33(0)1
44 71 20 41ljacquin@newcap.fr |
ORPHEON
FINANCEFinancial Communication and Investor
RelationsJames Palmer+33 7 60 92 77
74j.palmer@orpheonfinance.com |
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Aug 2023 to Aug 2024